Jinling Pharmaceutical announced that since submitting the “Letter of Intent to Invest” to the four pharmaceutical companies on April 13, 2026, the company has carried out due diligence, preliminary audits, asset evaluation, and transaction plan verification in an orderly manner, and has continued to communicate and negotiate with relevant parties on investment intentions. Recently, the company received an “Invitation Letter” from the four pharmaceutical companies. 100% of the shares of the four pharmaceutical companies and some of the land and plant assets of the four pharmaceutical companies are to be sold through bidding. According to materials such as the “Invitation Letter” received by the company and the “Bidding Operation Guidelines” attached to the letter, the company decided not to participate in this bidding activity and terminated the above investment intentions, taking into account the information already known earlier and after careful research.

Jinling Pharmaceutical announced that since submitting the “Letter of Intent to Investment” to the four pharmaceutical companies on April 13, 2026, the company has carried out due diligence, preliminary audits, asset evaluation, and transaction plan verification in an orderly manner, and has continued to communicate and negotiate with relevant parties on investment intentions. Recently, the company received an “Invitation Letter” from the four pharmaceutical companies. 100% of the shares of the four pharmaceutical companies and some of the land and plant assets of the four pharmaceutical companies are to be sold through bidding. According to materials such as the “Invitation Letter” received by the company and the “Bidding Operation Guidelines” attached to the letter, the company decided not to participate in this bidding activity and terminated the above investment intentions, taking into account the information already known earlier and after careful research.